PureTech Announces Successful End-of-Phase 1 Meeting with U.S. FDA and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

Press Release
Written By Jamison Wright

https://news.puretechhealth.com/news-releases/news-release-details/puretech-announces-successful-end-phase-1-meeting-us-food-and

Jamison Wright https://jamisonwright.com
Next

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)